

# Afghanistan

## COUNTRY GENERAL INFORMATION

Total population:	37 171 922
Gender F/M (%):	48.6 / 51.4
Population, age group <15 / ≥ 15 years (%):	43 / 57
Life expectancy at birth (F/M, years):	62 / 61
GDP (PPP int \$):	1952
Income status:	Low income
Number of 2 <sup>nd</sup> sub-national administrative level divisions, name:	399, District



## EPIDEMIOLOGY

	VL	ACL	ZCL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	23	35 015	3392	N/A
Number of relapses: <sup>1</sup>	No data	1775	8	N/A
<b>Total number of cases:</b>	<b>23</b>	<b>36 790</b>	<b>3400</b>	<b>N/A</b>
Imported cases (#, %):	No data	No data	No data	No data
Gender distribution (% F):	26	49	53	N/A
Age group distribution (% <5 / 5-14 / >14):	83 / 0 / 17	37 / 0 / 63	55 / 0 / 45	N/A
Incidence rate (cases/10 000 population in endemic areas):	0.05	13.66	23.51	N/A
Number of endemic 2 <sup>nd</sup> sub-national administrative level divisions:	34	310	15	N/A
Population at risk (% # at risk / total population): <sup>2</sup>	12% 4 304 147/ 37 171 922	69% 25 636 364/ 37 171 922	4% 1 442 847/ 37 171 922	N/A
Was there any outbreak?	No data	No data	No data	N/A
Number of new foci: <sup>3</sup>	No data	No data	No data	N/A



## Monthly distribution of new cases (January-December)

2018	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	0	1	1	2	3	2	4	0	3	3	0	4
ACL	3096	2928	3241	4199	2849	2080	2601	2016	2231	2871	3168	3,735
ZCL	237	14	75	43	35	20	25	49	299	872	914	809

N/A not applicable; VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis



## Number of new cases and Incidence rate/10 000 at the national level from 2003 to 2018





<sup>1</sup>Relapse in this country is defined for CL as: "Poor response to local or systemic treatment during follow up and the physician decides to start a second course"

<sup>2</sup>Defined as "Number of people living in 2nd sub-national administrative level endemic areas"

<sup>3</sup>Defined as "In this reporting period, an area at the 2nd sub-national administrative level reporting cases for the first time ever"

## Disease distribution of new VL, ACL and ZCL cases at District level per 10 000 population (2018)



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Map production: WHO/UCN/NTD

## CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	1968
Type of surveillance (CL / VL):	Vertical / Vertical
Is there a vector control programme?	No
Type of insecticide used for Indoor residual Spraying (IRS):	NA
Year latest national guidelines (CL / VL):	2004 / 2004
Is leishmaniasis notifiable (mandatory report)? (CL / VL):	No / No
Is there a reservoir host control programme?	No
Number of leishmaniasis health facilities (CL / VL):	553 / No data

## DIAGNOSIS

	VL	ACL	ZCL	MCL
Number of people screened actively for:	No data	No data	No data	N/A
Number of people screened passively for:	No data	No data	No data	N/A
VL cases diagnosed by RDT (% , # RDT+ / new VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT (% , # RDT+ / total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides + / total cases):	100% (23/23)	21% (7506/35 015)	5% (167/3392)	N/A
Proportion of positive slides (% , # slides + / total slides):	No data	No data	No data	N/A
Cases diagnosed clinically (% , # clinical cases / total cases):	0% (0/23)	79% (27 509/35 015)	95% (3225/3392)	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	N/A	N/A

N/A not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

## TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? (CL / VL): Yes / Yes
- ▶ Antileishmanial medicines included in the National Medicine List: Meglumine antimoniate, Sodium stibogluconate (SSG)

## INITIAL TREATMENT OUTCOME FOR NEW CASES

	VL	ACL	ZCL
Cases that completed treatment (% , # completed treatment / new cases):	No data	61% (21 212/35 015)	25% (862/3392)
Initial cure rate (% , # cases initially cured / new cases):	No data	45% (15 731/35 015)	27% (927/3392)
Failure rate (% , # cases with treatment failure / new cases): <sup>4</sup>	No data	1% (193/35 015)	0% (1/3392)
Case fatality rate (% , # cases who died / new cases):	No data	No data	No data

VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis

<sup>4</sup>Failure in this country is defined for CL as: "A patient who is not cured at the end of second course of the treatment"